$GILD · GILEAD SCIENCES, INC.

Gilead reported Q3 2026 results with total revenue of $8.3B (+7% YoY), driven by 16% growth in product sales excluding Veklury to $8.2B. Non-GAAP diluted EPS of $2.55 beat the prior-year $2.47, while GAAP diluted EPS fell to $1.94 from $2.43. The company raised full-year 2026 product sales guidance by $900M at the midpoint to $31.0B–$31.3B, though GAAP loss-per-share guidance widened due to $12.4B in acquired IPR&D charges.

Extended-hours trading shows shares at $169.60, up +2.41% vs. the $165.61 regular close, reflecting a positive reaction to the 16% base business growth and raised revenue guidance. The $205B market-cap biopharma is seeing after-hours buying on the strongest base business growth in over a decade.

Gilead delivered its strongest base business growth in more than a decade while simultaneously absorbing $12.4B in pipeline-building M&A charges — a high-conviction bet on future HIV and oncology franchises.

Gilead's 18% HIV growth and 42% Trodelvy oncology surge contrast with declining COVID-19 tailwinds across the biopharma sector. The aggressive M&A strategy — four acquisitions with $12.4B in IPR&D charges — mirrors the sector's push to replenish pipelines via bolt-on deals.

Cell Therapy sales fell 18% YoY to $355M amid ongoing competitive headwinds. Veklury revenue collapsed 69% to $86M as COVID-19 hospitalizations declined. The $12.4B in acquired IPR&D charges from four acquisitions (Arcellx, Tubulis, Ouro Medicines, PepStar) drove FY GAAP guidance to a deep loss.